NASDAQ:MNKD Archives - BioPharmaJournal

Mannkind Corporation (NASDAQ: MNKD) Announces FDA’s Approval for Tyvaso DPI

Gavins Felicity - June 1, 2022 0

MannKind Corporation (NASDAQ: MNKD) Plunges 29% after FDA Rejects NDA for...

Matt Wade - October 25, 2021 0

MannKind Corporation (NASDAQ: MNKD) Starts Paediatric Enrolment For INHALE-1 Study ...

Matt Wade - October 13, 2021 0

Mannkind Corporation (NASDAQ:MNKD) Enters Agreement With Vertice Pharma for Co-Promotion of...

Matt Wade - December 23, 2020 0

MannKind Corporation (NASDAQ:MNKD) Reports 27% YoY Growth In Afrezza Revenue In...

Kate Hudson - November 12, 2020 0

MannKind Corporation (NASDAQ:MNKD) Posts Revenues Of $15.1 Million In Q2 2020

Ward Sport - August 20, 2020 0

MannKind Corporation (NASDAQ:MNKD) Presents Encouraging Afrezza Clinical Study Data At The...

Matt Wade - June 25, 2020 0

CymaBay Therapeutics Inc (NASDAQ: CBAY) Announces Promising Seladelpar Data In Treatment...

Gavins Felicity - July 5, 2022 0

CymaBay Therapeutics Inc (NASDAQ: CBAY) has announced the presentation of promising seladelpar findings in primary biliary cholangitis (PBC) patients at The International Liver Congress...

Chimerix Inc (NASDAQ: CMRX) Receives $25.3 Million Procurement Contract For TEMBEXA

July 4, 2022

Regulus Therapeutics Inc (NASDAQ: RGLS) Pleased after FDA Approved its Orphan...

July 1, 2022

Cannabis Stocks Deeply Oversold with Big Growth Ahead (TLRY, SGMD, OGI,...

June 30, 2022

Ocugen Inc (NASDAQ: OCGN) Announces the Successful Publication of Positive Outcomes...

June 30, 2022

Tag: NASDAQ:MNKD

Recent Post